Skip to main content

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics

  • Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSD
  • These results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizon
  • Mydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds by undertaking clinical research in partnership with academics
  • In a recent interview, company CEO Josh Bartch emphasized the need for consistent messaging to push the adoption of psychedelics among the medical community, and help assuage concerns of patients who may be wary of psychedelic treatments

Fueled by the extremes of the counterculture witnessed in the ‘60s and ‘70s, psychedelics acquired a soiled reputation that drove stereotypical connotations, which are only wearing off years later thanks to efforts by researchers. Results from one study published in the New England Journal of Medicine, for example, showed the benefits of using psilocybin as a treatment for depression (https://ibn.fm/LfyUe). Another clinical trial published in the Nature Medicine journal established that MDMA (commonly known as Ecstasy and Molly) combined with counseling brought noticeable relief to patients with severe post-traumatic stress disorder (“PTSD”) (https://ibn.fm/rEBcb).

As a result, a 2021 New York Times article observed that the scientific and psychotherapeutic communities had been enthused, further noting that “[scientists, psychotherapists, and entrepreneurs in the field of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.